Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation

被引：0
|
作者：
Rugo, H. S. [1 ]
Quek, R. [2 ]
Ettl, J. [3 ]
Hurvitz, S. A. [4 ]
Bhattacharyya, H. [2 ]
Hannah, A. L. [5 ]
Litton, J. K. [6 ]
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, Breast Canc Ctr, San Francisco, CA USA
[2] Pfizer Inc, Hlth Econ, San Francisco, CA USA
[3] Tech Univ Munich, Obs Gyn, Munich, Germany
[4] Univ Calif Los Angeles, Hematol Oncol, Santa Monica, CA USA
[5] Pfizer Inc, Oncol, San Francisco, CA USA
[6] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
292O
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Patient-reported outcomes (PRO) in patients (pts) with BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study
    Rathkopf, Dana E.
    Roubaud, Guilhem
    Chi, Kim N.
    Efstathiou, Eleni
    Attard, Gerhardt
    Olmos, David
    Small, Eric J.
    Saad, Marniza
    Castro, Elena
    Kim, Won
    Wu, Daphne
    Bertzos, Kristi
    Dibaj, Shiva
    Zhang, Jenny
    Francis, Peter St. John
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 105 - 105
  • [42] Treatment patterns and clinical outcomes among patients (pts) with HER2-advanced breast cancer (ABC) and germline BRCA1/2 mutation(s) (gBRCA1/2mut): results from a US real-world study
    Obeid, Elias
    Parikh, Rohan C.
    Esterberg, Elizabeth
    Arondekar, Bhakti
    Hitchens, Abigail
    Arruda, Lillian Shahied
    Niyazov, Alexander
    CANCER RESEARCH, 2021, 81 (04)
  • [43] Treatment patterns and clinical outcomes among patients (pts) with HER2+advanced breast cancer (ABC) and germline BRCA1/2 mutation(s) (gBRCA1/2mut): Results from a US real-world study.
    Obeid, Elias
    Parikh, Rohan
    Esterberg, Elizabeth
    Arondekar, Bhakti
    Hitchens, Abigail
    Arruda, Lillian Shahied
    Niyazov, Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
    Ueno, N. T.
    Jacot, W.
    Yamashita, T.
    Sohn, J.
    Tokunaga, E.
    Prat, A.
    Tsurutani, J.
    Park, Y. H.
    Rugo, H. S.
    Xu, B.
    Cardoso, F.
    Mitri, Z.
    Mahtani, R.
    Dunton, K.
    Wang, Y.
    Gambhire, D.
    Cottone, F.
    Harbeck, N.
    Cameron, D. A.
    Modi, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S632 - S633
  • [45] Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel
    Mahtani, Reshma
    Niyazov, Alexander
    Arondekar, Bhakti
    Lewis, Katie
    Rider, Alex
    Massey, Lucy
    Lux, Michael Patrick
    BREAST, 2022, 66 : 236 - 244
  • [46] Patient reported outcomes (PROs) with poly(ADP-ribose) polymerase inhibitors (PARPi) versus chemotherapy (CTX) in patients (pts) with germline BRCA1/2 mutated (gBRCA1/2mut) HER2-advanced breast cancer (ABC): Results from a multicountry real-world (RW) study
    Mahtani, Reshma
    Niyazov, Alexander
    Lewis, Katie
    Pike, James
    Rider, Alex
    Arondekar, Bhakti
    Lux, Michael Patrick
    CANCER RESEARCH, 2021, 81 (04)
  • [47] Treatment patterns and clinical outcomes among patients (pts) with HER2-advanced breast cancer (ABC) and somatic BRCA1/2 mutation(s) (sBRCA1/2mut): Results from a US real-world study
    Obeid, Elias
    Parikh, Rohan C.
    Esterberg, Elizabeth
    Arondekar, Bhakti
    Hitchens, Abigail
    Arruda, Lillian Shahied
    Niyazov, Alexander
    CANCER RESEARCH, 2021, 81 (04)
  • [48] Patient-reported outcomes (PkOs) from TH3RESA, a phase 3 study of trastuzumab emtansine, (T-DM1) versus treatment of physician's choice (TPC) in patients With pretreated HER2-positive advanced breast cancer.
    Bartley, Karen
    Wildiers, Hans
    Kim, Sung-Bae
    Krop, Ian E.
    Kang, Jennifer
    Yu, Ron
    Leung, Abraham C. F.
    Trudeau, Caroline
    Gonzalez-Martin, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [49] Treatment Patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with or without, or with Unknown, BRCA1/2 Mutation(s): Results of a Real-World Study from the United States, United Kingdom, and four EU Countries
    Lux, Michael Patrick
    Lewis, Katie
    Rider, Alex
    Niyazov, Alexander
    BREAST CARE, 2022, 17 (05) : 460 - 469
  • [50] Treatment Patterns, Safety, and Patient-Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with or without Unknown BRCA1/2 Mutation(s): Results of a Real-World Study from the United States, United Kingdom, and Four EU Countries (vol 17, pg 460, 2022)
    Lux
    BREAST CARE, 2022, 17 (04) : 437 - 437
12345